New Variant of MYH7 Gene Nucleotide Sequence in Familial Non-Compaction Cardiomyopathy with Benign Course

Left ventricular non-compaction (LVNC) is a genetically determined cardiomyopathy characterized by different variants of the clinical course. LVNC family cases allow to study in more details the role of genetic factors in cardiomyopathy pathogenesis and prognosis, as well as to determine clinical course features.

Aim. To demonstrate a case of LVNC familial form with a stable benign course and to assess the possible relationship of the detected mutation with the disease prognosis.

Material and methods. A family with LVNC was included in the study. The patient with LVNC and his 1st and 2nd degree of kinship relatives underwent clinical and instrumental examination and exome sequencing. LVNC was diagnosed in proband and proband's father. LVNC diagnosis was established basing on echo and magnetic resonance imaging (MRI) criteria.

Results. This article presents the results of a comprehensive clinical and instrumental examination of a family with LVNC with a new variant in the MYH7 gene, the absence of intramyocardial fibrosis according to MRI of the heart and a favorable disease course, both in proband's father and proband himself. A comparative analysis of the data obtained with the results of recent large-scale studies and meta-analyses devoted to the study of prognostic factors in patients with LVNC, with identified variants in the MYH7 gene.

Conclusions. The variant of p.His1338Pro identified in the MYH7 gene may be associated with the development of LVNC with a benign course.

1. Hoedemaekers Y.M., Caliskan K., Michels M., et al. The importance of genetic counseling, DNA diagnostics, and cardiologic family screening in left ventricular non-compaction cardiomyopathy. Circulation Cardiovascular genetics. 2010;3(3):232-9. DOI:10.1161/CIRCGENETICS.109.903898.

2. Caliskan K., Michels M., Geleijnse M.L., et al. Frequency of Asymptomatic Disease Among Family Members With Non-compaction Cardiomyopathy. The American Journal of Cardiology. 2012;110(10):1512-7. DOI:10.1016/j.amjcard.2012.07.009.

3. Мясников Р.П., Щербакова Н.В., Куликова О.В. и др. Мутация гена DES в семье пробанда с миофибриллярной миопатией и развитием некомпактной кардиомиопатии, приведшей к трансплантации сердца. Российский Кардиологический Журнал. 2017;10(150):9-16. DOI:10.15829/1560-4071-2017-10-9-16.

4. Finsterer J., Stollberger C. Primary prophylactic anticoagulation is mandatory if non-compaction is associated with atrial fibrillation or heart failure. International Journal of Cardiology. 2015;184(1):268-69. DOI:10.1016/j.ijcard.2015.02.041.

5. Jacquier A., Thuny F., Jop B., et al. Measurement of trabeculated left ventricular mass using cardiac magnetic resonance imaging in the diagnosis of left ventricular non-compaction. Eur Heart J. 2010;31(9):1098-104. DOI:10.1093/eurheartj/ehp595.

6. Petersen S.E., Selvanayagam J.B., Wiesmann F., et al. Left Ventricular Non-Compaction. Journal of the American College of Cardiology. 2005;46(1):101-5. DOI:10.1016/j.jacc.2005.03.045.

7. Richards S., Aziz N., Bale S., et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-24. DOI:10.1038/gim.2015.30.

8. Kayvanpour E., Sedaghat-Hamedani F., Gi W.T., et al. Clinical and genetic insights into non-compaction: a meta-analysis and systematic review on 7598 individuals. Clin Res Cardiol. 2019;108(11):1297-308. DOI:10.1007/s00392-019-01465-3.

9. Мясников Р.П., Благова О.В., Куликова О.В. и др. Особенности манифестации некомпактной кардиомиопатии. Кардиоваскулярная Терапияи Профилактика. 2015;14(5):78-82. DOI:10.15829/1728-8800-2015-5-78-82.

10. Li S., Zhang C., Liu N., et al. Genotype-positive status is associated with poor prognoses in patients with left ventricular non-compaction cardiomyopathy. Journal of the American Heart Association. 2018;7(20). DOI:10.1161/JAHA.118.009910.

11. van Waning J.I., Caliskan K., Hoedemaekers Y.M., et al. Genetics, Clinical Features, and Long-Term Outcome of Non-compaction Cardiomyopathy. Journal of the American College of Cardiology. 2018;71(7):711-22. DOI:10.1016/j.jacc.2017.12.019.

12. Sedaghat-Hamedani F., Haas J., Zhu F., et al. Clinical genetics and outcome of left ventricular noncompaction cardiomyopathy. Eur Heart J. 2017;38(46):3449-60. DOI:10.1093/eurheartj/ehx545.

13. Masci P.G., Barison A., Aquaro G.D., et al. Myocardial delayed enhancement in paucisymptomatic nonischemic dilated cardiomyopathy. International journal of cardiology. 2012;157(1):43-7. DOI:10.1016/j.ijcard.2010.11.005.

14. Gulati A., Jabbour A., Ismail T.F., et al. Association of Fibrosis With Mortality and Sudden Cardiac Death in Patients With Nonischemic Dilated Cardiomyopathy. JAMA. 2013;309(9):896. DOI:10.1001/jama.2013.1363.

15. Assomull R.G., Prasad S.K, Lyne J., et al. Cardiovascular Magnetic Resonance, Fibrosis, and Prognosis in Dilated Cardiomyopathy. Journal of the American College of Cardiology. 2006;48(10):1977-985. DOI:10.1016/j.jacc.2006.07.049.

16. Amzulescu M.S., Rousseau M.F., Ahn S.A., et al. Prognostic Impact of Hypertrabeculation and Noncompaction Phenotype in Dilated Cardiomyopathy. JACC: Cardiovascular Imaging. 2015;8(8):934-46. DOI:10.1016/j.jcmg.2015.04.015.

17. Andreini D., Pontone G., Bogaert J., et al. Long-Term Prognostic Value of Cardiac Magnetic Resonance in Left Ventricle Non-compaction. Journal of the American College of Cardiology. 2016;68(20):2166-81. DOI:10.1016/j.jacc.2016.08.053.

18. Mazurkiewicz I., Petryka J., Spiewak M., et al. Clinical and prognostic relevancy of left ventricular trabeculation assessed by cardiac magnetic resonance in patients with dilated cardiomyopathy. Kar-diol Pol. 2017;75(8):794-803. DOI:10.5603/KP.a2017.0097.

19. Ivanov A., Dabiesingh D.S., Bhumireddy G.P., et al. Prevalence and Prognostic Significance of Left Ventricular Non-compaction in Patients Referred for Cardiac Magnetic Resonance Imaging. Circ Car-diovasc Imaging. 2017;10(9). pii:e006174. DOI:10.1161/CIRCIMAGING.117.006174.

20. Grigoratos C., Barison A., Ivanov A., et al. Meta-Analysis of the Prognostic Role of Late Gadolinium Enhancement and Global Systolic Impairment in Left Ventricular Non-compaction. JACC Cardiovasc Imaging. 2019;12(11 Pt 1):2141-2151. DOI:10.1016/j.jcmg.2018.12.029.

21. Luijkx T., Cramer M.J., Zaidi A., et al. Ethnic differences in ventricular hypertrabeculation on cardiac MRI in elite football players. Netherlands Heart Journal. 2012;20(10):389-95. DOI:10.1007/s12471-012-0305-7.

22. Caselli S., Ferreira D., Kanawati E., et al. Prominent left ventricular trabeculations in competitive athletes: A proposal for risk stratification and management. International Journal of Cardiology. 2016;223:590-5. DOI:10.1016/j.ijcard.2016.08.272.

23. Gati S., Papadakis M., Papamichael N.D., et al. Reversible De Novo Left Ventricular Trabeculations in Pregnant Women. Circulation. 2014;130(6):475-83. DOI:10.1161/CIRCULATION-AHA.114.008554.